Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer This investment positions France at the forefront of this innovative cancer treatment technology and is part of broader industrial commitments in France, covering European demand for targeted prostate cancer therapy […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.